Researchers at the University of Cambridge have uncovered how targeting a specific brain receptor can lead to weight loss in different ways. Their study found that activating the glucose-dependent insulinotropic polypeptide receptor (GIPR) in the brainstem reduces appetite, while blocking the same receptor in the hypothalamus enhances feelings of fullness. This dual approach offers insights into why various obesity medications can achieve similar weight loss results, even when they seem to work in opposite ways.

This discovery is particularly relevant for the more than one billion people worldwide living with obesity, a condition linked to serious health risks like type 2 diabetes and heart disease. For those looking to lose weight, understanding how these treatments work could lead to more effective solutions. The study suggests that combining GIPR-targeting drugs with popular medications like Wegovy and Ozempic could enhance their weight loss effects, making it easier for people to manage their weight and improve overall health.

The research involved experiments on genetically modified mice, revealing that the effectiveness of GIPR drugs depends on the brain region targeted. While activating GIPR in the brainstem decreased appetite, blocking it in the hypothalamus released a “brake” on fullness signals, promoting weight loss. Although these findings are based on animal studies, they provide a promising foundation for developing more effective obesity treatments in humans. As researchers continue to explore these mechanisms, there is hope for creating medications that not only promote weight loss but also minimize side effects.

Source